Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia (SCORE)

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Schizophrenia

Treatments: Drug: Quetiapine fumarate; Drug: conventional treatment for schizophrenia

Study type: Interventional

Funder types: Industry

Identifiers

NCT00255515

D1449L00004

SCORE

Details and patient eligibility

About

The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.

Enrollment: 85 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Documented clinical diagnosis of schizophrenia or schizoaffective disorder for at least 2 years.
• Clinically stable and in an outpatient setting before entering the study (visit 1).

Exclusion criteria

• Use of clozapine and quetiapine within two months prior to visit 1.
• If total points are ≤ 55 Intelligence quotient (IQ) according to score of WAIS-III test at visit 1.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

85 participants in 3 patient groups

1

Experimental group

Description:

quetiapine fumarate

Treatment:

Drug: Quetiapine fumarate

2

Active Comparator group

Description:

Conventional treatment for schizophrenia

Treatment:

Drug: conventional treatment for schizophrenia

3

Experimental group

Description:

quetiapine fumarate + Cognitive Remediation Therapy

Treatment:

Drug: Quetiapine fumarate